3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
5
Prostatic Neoplasms
4
Melanoma
4
Small Cell Lung Carcinoma
3
Prostatic Neoplasms, Castration-Resistant
3
Colorectal Neoplasms
3
Breast Neoplasms
3
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Pancreatic Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Hepatocellular
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasms, Squamous Cell
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Neoplasm Metastasis
1
NSCLC Harboring NRG1 Fusion
1
Mesothelioma, Malignant
1
Mesothelioma
1
Lymphoproliferative Disorders
1
Lymphoma, T-Cell
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Interventions
Cisplatin
6
Etoposide
5
Topotecan
4
Carboplatin
4
Pemetrexed
3
Gemcitabine
3
belinostat
2
Temozolomide
2
RRx-001
2
vosaroxin
1
vinflunine
1
veliparib
1
taxane
1
sagopilone
1
sacituzumab govitecan
1
pembrolizumab
1
lurtotecan
1
liposomal doxorubicin
1
enzalutamide
1
bemiparin
1
belotecan
1
atezolizumab
1
apalutamide
1
alvocidib
1
abiraterone
1
Vinorelbine
1
Tomography, X-Ray Computed
1
Sorafenib
1
Rhenium
1
Radiation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Small Cell
×
enzalutamide
×
Thoracic
×
Clear all
NCT05551117
2026-02-09
Tamarack
MacroGenics
Phase 2
Terminated
192 enrolled
20 charts